Trade Mark Journal No.2026/014 3 April 2026

UK00004359796 23 March 2026 (5)

DUHUNTTYX

International priority date claimed: 5 March 2026 (United States of America) (99684307)

Class 5: Pharmaceuticals, namely, small molecule therapeutic preparations for the correction of RNA expression and alteration of RNA translation, used in the treatment of Huntington’s Disease.

Skyhawk Therapeutics, Inc.

Representative: Appleyard Lees IP LLP